Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL
NCT07172893 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this clinical evaluation is to collect patient outcome data and evaluate the efficacy, safety and tolerability of HealthTech DermaBind TL™ in patients with chronic non-healing wounds in patients with chronic non-healing ulcers.
Conditions Studied
Interventions
- BIOLOGICAL DermaBind TL
Study Locations (10)
Florida
- Midland Florida Clinical Research Center — DeLand
- Pharmakon Medical Research — Palm Beach Gardens
- Vital Medical Research — Sweetwater
North Carolina
- US Foot and Ankle Specialists-Cary Satellite Site — Cary
- US Foot and Ankle Specialists — Raleigh
Ohio
- US Foot and Ankle Specialists — Blue Ash
- Lower Extremity Institute for Research and Therapy — Boardman
Michigan
- EMbassy Research Network — Bloomfield Township
Texas
- Perfizien Clinical Research, LLC. — Houston
Virginia
- Foot and Ankle Specialists of the Mid-Atlantic — Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-12-10 |
| Est. Completion | 2027-05-21 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07172893
The ClinicalTrials.gov registry entry for NCT07172893 describes a study currently listed as recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HealthTech Wound Care, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Diabetic Foot Ulcer (DFU) appearing as the primary indexed condition, and to 1 intervention — of which DermaBind TL is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07172893 reports 10 study locations spanning 6 distinct geographic areas — top geographies include Florida, North Carolina, Ohio. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07172893 about?
NCT07172893 is a clinical study titled "A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL". The purpose of this clinical evaluation is to collect patient outcome data and evaluate the efficacy, safety and tolerability of HealthTech DermaBind TL™ in patients with chronic non-healing wounds in patients with chronic non-healing ulcers.
What is the current status of trial NCT07172893?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2025-12-10. Estimated completion is 2027-05-21.
What conditions does trial NCT07172893 study?
This clinical trial studies the following conditions: Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07172893?
The interventions under investigation include: DermaBind TL (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07172893?
This trial is sponsored by HealthTech Wound Care, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07172893 being conducted?
This trial has 10 study locations across Florida, Michigan, North Carolina, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.